Surgery Partners, Inc.

Listed Company

SGRYCIK 0001638833NasdaqLarge AcceleratedServices-General Medical & Surgical Hospitals, NecDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-77.90M

Total Assets

$8.12B

Equity

$1.71B

Shares Out

130.79M

Op. Cash Flow

$274.30M

SGRY$16.01−29.24% · past yearDBEQ Basic

Daily closing prices

Business

Surgery Partners, Inc. owns and operates a national network of surgical facilities and ancillary services, including ambulatory surgery centers (ASCs), short-stay surgical hospitals, and multi-specialty physician practices across more than 200 locations in 30 states. The company generates revenue primarily from facility fees for surgical procedures and management fees from non-consolidated facilities it manages. Surgery Partners operates through partnerships and limited liability companies with physicians, physician groups, and health care systems, competing with hospitals and other surgical facility operators to attract both physicians and patients.

Summary from 10-K filed 2026-03-02

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	3,309	3,114	2,743	2,539	2,225
Salaries and benefits	971	908	794	746	644
Supplies	879	813	745	710	636
Professional and medical fees	405	357	297	269	230
Lease expense	88	90	85	82	91
Other operating expenses	201	202	175	157	132
Cost of revenues	2,544	2,369	2,096	1,964	1,734
General and administrative expenses	118	139	121	102	104
Depreciation and amortization	176	153	118	115	99
Transaction and integration costs	74	100	62	48	40
Net loss on disposals, consolidations and deconsolidations	30	41	14	11	2
Equity in earnings of unconsolidated affiliates	−23	−20	−14	−13	−11
Litigation settlements	7	−800,000	11	−29	0
Loss on debt extinguishment	1	5	16	15	9
Other income, net	−9	−20	−8	−19	−16
Total operating expenses	2,919	2,766	2,415	2,194	1,923
Operating income	390	349	328	345	302
Interest expense, net	−273	−202	−193	−235	−221
Income before income taxes	117	147	135	110	81
Income tax (expense) benefit	−18	−135	300,000	−23	−11
Net income	99	13	135	87	71
Less: Net income attributable to non-controlling interests	−177	−181	−147	−142	−142
Net loss attributable to Surgery Partners, Inc.	−78	−168	−12	−55	−71
Basic (in USD per share)	−0.61	−1.33	−0.09	−0.59	−1.12
Diluted (in USD per share)	−0.61	−1.33	−0.09	−0.59	−1.12
Basic (shares)	127	126	126	92	72
Diluted (shares)	127	126	126	92	72

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	240	270	196	283	390
Accounts receivable	602	579	496	456	430
Inventories	97	88	75	71	61
Prepaid expenses	41	36	31	31	26
Other current assets	171	146	97	79	39
Total current assets	1,151	1,119	895	921	946
Property and equipment, net	1,153	1,088	969	877	630
Intangible assets, net	41	46	55	42	44
Goodwill	5,195	5,068	4,326	4,137	3,912
Investments in and advances to affiliates	234	215	184	190	89
Right-of-use operating lease assets	289	296	255	279	324
Other long-term assets	57	58	103	144	59
Total assets	8,120	7,890	6,877	6,682	6,118
Accounts payable	209	209	172	152	125
Accrued payroll and benefits	65	60	74	69	77
Other current liabilities	243	254	204	210	210
Current maturities of long-term debt	99	101	73	63	60
Total current liabilities	616	624	523	493	537
Long-term debt, less current maturities	3,603	3,269	2,702	2,559	2,878
Right-of-use operating lease liabilities	280	292	249	271	316
Long-term deferred tax liabilities	53	39	0	—	—
Other long-term liabilities	41	30	41	75	87
Non-controlling interestsredeemable	396	439	327	342	330
Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none	0	0	0	0	0
Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 129,321,144 and 127,109,383, respectively	1	1	1	1	900,000
Additional paid-in capital	2,541	2,521	2,498	2,478	1,622
Accumulated other comprehensive (loss) income	−14	5	58	76	−32
Retained deficit	−815	−737	−569	−557	−503
Total Surgery Partners, Inc. stockholders' equity	1,713	1,790	1,987	1,998	1,089
Non-controlling interestsnon-redeemable	1,418	1,407	1,047	943	881
Total stockholders' equity	3,131	3,196	3,035	2,941	1,970
Total liabilities and stockholders' equity	8,120	7,890	6,877	6,682	6,118

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Non-cash lease expense	38	39	35	35	39
Non-cash interest expense, net	10	7	25	26	22
Equity-based compensation expense	15	33	18	18	17
Deferred income taxes	17	132	−2	22	9
Equity in earnings of unconsolidated affiliates, net of distributions received	−800,000	−2	−2	−2	200,000
Accounts receivable	−54	−72	−47	−35	−32
Other operating assets and liabilities	−57	−47	−16	−67	−43
Net cash provided by operating activities	274	300	294	159	87
Purchases of property and equipment	−79	−90	−89	−81	−58
Payments for acquisitions, net of cash acquired	−162	−379	−80	−146	−286
Proceeds from disposals of facilities and other assets	47	3	26	13	6
Purchases of equity investments	−13	−2	−50	−95	0
Proceeds from sales of equity investments	2	5	1	13	5
Other investing activities	−41	−25	−34	−12	300,000
Net cash used in investing activities	−247	−489	−226	−308	−332
Principal payments on long-term debt	−1,040	−1,279	−807	−862	−343
Borrowings of long-term debt	1,203	1,730	827	218	299
Payments of debt issuance costs	−4	−15	−24	0	−12
Distributions to non-controlling interest holders	−226	−171	−146	−147	−131
Proceeds (payments) related to ownership transactions with non-controlling interest holders	600,000	10	8	−3	−28
Other financing activities	9	−13	−13	−10	−18
Net cash (used in) provided by financing activities	−57	262	−155	42	316
Net (decrease) increase in cash and cash equivalents	−30	74	−87	−107	72
Interest paid, net of interest income received	257	200	170	219	194
Cash paid for income taxes	1	2	1	2	2
Non-cash purchases of property and equipment	14	13	18	30	22

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Surgery Partners, Inc.'s CIK number?

Surgery Partners, Inc.'s SEC CIK number is 0001638833 (1638833). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Surgery Partners, Inc.'s SEC filings?

All of Surgery Partners, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Surgery Partners, Inc. last report earnings?

Surgery Partners, Inc. (SGRY) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001638833-26-000044). This is Surgery Partners, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Surgery Partners, Inc.'s most recent earnings 8-K?

Surgery Partners, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001638833-26-000044. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Surgery Partners, Inc.'s latest earnings 8-K →
Look up any company's CIK number →